For decades, the field of tuberculosis (TB) immunology has focused on T cell mediated protection, yet Mycobacterium tuberculosis (Mtb) still impacts one in four individuals worldwide today.

Please contact our team if planning neoadjuvant Adriamycin (doxorubicin), for enrollment in the HP Cardiotox Study.

Research in the Rothermel Laboratory focuses on deciphering the molecular mechanisms that control cardiac structure and function during normal development and in response to pathological stress.

The goal of our research is to identify key immune checkpoints of gastrointestinal disorders that could be targeted for therapeutic intervention and drug development.

The ultimate aim of the Shiloh Lab is to contribute to the development of vaccines and treatments for Mycobacterium tuberculosis (Mtb).

Burstein Laboratory focuses on understanding the regulation of the inflammatory response at a molecular level, and elucidating how these events may participate in human disease.